E-Mail
The primary cilium, an antenna-like subcellular structure ( organelle ) protruding from the outside of many types of vertebrate cells, has an important but previously overlooked role in guiding the growth of lymphatic vessels, shows a new study. The authors show for the first time that mouse and human lymphatic endothelial cells (LECs) - which make up the inner and outer lining of lymphatic vessels - use primary cilia. They find that LEC primary cilia may direct the growth of a functional lymphatic network, not only during prenatal development, but also throughout life during inflammation and wound healing and in response to cancer. They show that mice in which the formation of primary cilia in LECs is prevented develop lymphatic vessels that are locally overgrown, suggesting that signals received by primary cilia may guide proper lymphatic vessel growth patterns. These results, published today in the open access journal
American Skin Association Announces 2021 Research Grants for Skin Cancer and Diseases
News provided by
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ American Skin Association has announced the awarding of two coveted research grants under the
ASA Milstein Research Scholar Awards program
.
ASA Milstein Research Scholar Award for Melanoma/Non-Melanoma Skin Cancer and
Ester Del Duca, MD of the Icahn School of Medicine at Mount Sinai received the
ASA Milstein Research Scholar Award in Atopic Dermatitis.
This year of grants includes the
ASA Daneen & Charles Stiefel Investigative Scientist Award in Melanoma Research awarded to
Elena Piskonouva, PhD of Weill Cornell Medicine. The Stiefel Family, longtime supporters of ASA, generously contributed $300,000 to support grants for melanoma research. The purpose of this funding is to identify and support emerging leaders in dermatology focused on melanoma research. Specifically catering to mid-ca
Baystate Health specialist part of team working to identify inequities, assist most vulnerable
Updated May 10, 2021;
SPRINGFIELD Dr. Paul Pirraglia, a Baystate Health internal medicine and public health specialist, has been part of a group meeting remotely since last March to identify those whose economic and social resources made them particularly vulnerable to COVID-19
The group includes other Baystate representatives, as well as members from the Public Health Institute of Western Massachusetts and Caring Health Center, and plans to continue its work even as COVID-19 cases have dropped regionally and across the state along with hospitalizations and deaths from complications of the respiratory disease.
Exotic locations across the world which share the same name as Worcester
You might know everything about Worcester in Worcestershire- but how well do you know the Worcester in South Africa? There are so many places in the world that share the same name as our humble city- so make sure you don’t accidentally book a trip to our sister destinations across the pond. According to
Geotargit, there are 10 places in the world named Worcester and they can be found in four countries throughout the world. Each of these areas has their own unique populations and attractions to explore.
Operator
Good morning, and welcome to the Iveric Bio first-quarter 2021 earnings conference call. [Operator instructions] Please note this call is being recorded. I would now like to turn the conference over to Kathy Galante, senior vice president, investor relations. Please go ahead.
Kathy Galante
Senior Vice President, Investor Relations
Good morning, and welcome to Iveric Bio s conference call. Representing Iveric Bio today are Glenn Sblendorio, chief executive officer; Pravin Dugel, president; David Carroll, chief financial officer; Dhaval Desai, chief development officer; Abraham Scaria, chief scientific officer; and Keith Westby, chief operating officer. I would like to remind you that today, we will be making statements relating to Iveric Bio s future expectations regarding operational, financial and research and development matters, including statements regarding our expectations for patient enrollment and patient retention in GATHER2, our second Phase 3 clinical trial